Long-term Immunogenicity and Safety Profile of the Adjuvanted RSVPreF3 Vaccine in Korean Older Adults: A Sub-analysis of a Phase 3 Trial

Seong-Beom Park, Suryaprakash Mishra, Sang-Kyu Shin, Stebin Xavier, Giulia Zigon, Manuel Zocco, Marie Van Der Wielen, Dong-Gun Lee, on behalf of the AReSVi-006 study group · 2026

Read Long-term Immunogenicity and Safety Profile of the Adjuvanted RSVPreF3 Vaccine in Korean Older Adults: A Sub-analysis of a Phase 3 Trial by Seong-Beom Park, Suryaprakash Mishra, Sang-Kyu Shin, Stebin Xavier, Giulia Zigon, Manuel Zocco, Marie Van Der Wielen, Dong-Gun Lee, on behalf of the AReSVi-006 study group (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13655466.txt.

Description

Seong-Beom Park and co-authors report long-term results for an RSV vaccine in Korean older adults, in work from 2026. RSV, a common lung virus, poses a grave risk to older adults. A vaccine with an immune booster has shown strong protection in a world trial.

The Korean arm of that trial held 719 adults aged 60 and older at twelve sites. Half got one shot of the vaccine, and half got a dummy shot. This follow-up tracks immune levels for two years after the shot. It also logs side effects from days to six months out. Local data matter since response can vary by population. Results help Korean health planners judge a rollout.

Catalog record

CREATORSeong-Beom Park, Suryaprakash Mishra, Sang-Kyu Shin, Stebin Xavier, Giulia Zigon, Manuel Zocco, Marie Van Der Wielen, Dong-Gun Lee, on behalf of the AReSVi-006 study group
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE33 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13655466

Browse the full library · About the Tower of Babel